BIIB · Biogen Inc.
$214.35
-7.21 (-3.25%)
At close · Aug 20
Market Cap
$31.38B
Shares
147.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$214.35
Open$217.98
Day$214.16–221.29
52W close$132.22–221.56
Avg vol 30d1.2M
Short int5.5M · 3.7% float · 4.7d
Short vol49%
Last earningsJul 29, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 29, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Low
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+5%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
92%
near high
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+12%
trailing
YTD return
+22%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $205 › 200d $188 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +125 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.69% of float · ▼ -9.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,039 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
118%
contracting
EPS growth
−21%
Y/Y
Free cash flow
$2.1B
Buyback
$5.0B
authorized
Balance sheet
$2.9B
net cash
Quant / Vol
risk profile
Volatility
36%
annualized · 1-yr
Max drawdown
−14%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Transaction run rate synergies
· exiting 2027
at least $250M
Prior guidance
period ended
· from the 8-K filed Jul 1, 2026
GAAP and non-GAAP net income per diluted share
· second quarter of 2026
$0.95
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $205 › 200d $188 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +125 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.69% of float · ▼ -9.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,039 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $132
Now $214 · 92%
Range high $222
vs 200-day avg +14%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EMPAVELI revenue | $46M | Q2 2026 | — |
| Free cash flow non-GAAP | $408M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 448.9M
-40.9M Purchases of property, plant and equipment
= Free cash flow 408M
|
|||
| Growth Portfolio revenue | $1.06B | Q2 2026 | — |
| Legacy MS Portfolio revenue | $767M | Q2 2026 | — |
| LEQEMBI global in-market sales | $184M | Q2 2026 | — |
|
|
|||
| LEQEMBI U.S. in-market sales | $97M | Q2 2026 | — |
|
|
|||
| Revenue change at constant currency non-GAAP | 1.6% | Q2 2026 vs. Q2 2025 | — |
| SKYCLARYS revenue | $168M | Q2 2026 | +28.9% |
|
|
|||
| SPINRAZA revenue | $402M | Q2 2026 | +2.4% |
|
|
|||
| SYFOVRE revenue | $162M | Q2 2026 | — |
| Total Contract Manufacturing, Royalty and Other Revenue change at constant currency non-GAAP | -4.5% | Q2 2026 vs. Q2 2025 | — |
| Total diluted earnings per share, Non-GAAP non-GAAP | $3.6 | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total diluted earnings per share, GAAP $0.66
+$2.94 (Less) Plus: adjustments to GAAP net income attributable to Biogen Inc.
= Total diluted earnings per share, Non-GAAP $3.6
|
|||
| Total effective tax rate, Non-GAAP non-GAAP | 17.2% | Q2 2026 | — |
| Total MS Product Revenue change at constant currency non-GAAP | -14.4% | Q2 2026 vs. Q2 2025 | — |
| Total net income attributable to Biogen Inc., Non-GAAP non-GAAP | 536.2M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total net income attributable to Biogen Inc., GAAP 97.5M
+1.1M litigation matter
+200.6M amortization of inventory fair value step-up
+0M impairment charges
+28.2M acquisition-related transaction and integration costs
+153.6M amortization of acquired intangible assets
+170.5M restructuring charges and other cost saving initiatives
+2.5M (gain) loss on fair value remeasurement of contingent consideration
-42.8M (gain) loss on equity security investments
-76.2M income tax effect related to Non-GAAP reconciling items
+1.2M other
= Total net income attributable to Biogen Inc., Non-GAAP 536.2M
|
|||
| Total Other Product Revenue change at constant currency non-GAAP | 51.4% | Q2 2026 vs. Q2 2025 | — |
| Total Rare Disease Revenue change at constant currency non-GAAP | 8.8% | Q2 2026 vs. Q2 2025 | — |
| Total Revenue from Alzheimer's Collaboration Revenue change at constant currency non-GAAP | 16% | Q2 2026 vs. Q2 2025 | — |
| Total Revenue from Anti-CD20 Therapeutic Programs change at constant currency non-GAAP | 9.8% | Q2 2026 vs. Q2 2025 | — |
| VUMERITY second quarter revenue | $197M | Q2 2026 | -7.2% |
|
|
|||
| Weighted average diluted shares | 149M | Q2 2026 | — |
| ZURZUVAE revenue | $71M | Q2 2026 | +53.0% |
|
|
|||
| QALSODY global revenue | 33M | Q1 2026 | — |
| SKYCLARYS global revenue | 151M | Q1 2026 | — |
| SPINRAZA global revenue | 374M | Q1 2026 | — |
| VUMERITY global revenue | 179M | Q1 2026 | — |
| Full year 2025 revenue from growth products year-over-year change | 19% | FY 2025 | — |
| LEQEMBI fourth quarter global in-market sales | 134M | Q4 2025 | — |
| LEQEMBI fourth quarter U.S. in-market sales | 78M | Q4 2025 | — |
| SKYCLARYS fourth quarter ex-U.S. revenue | 44M | Q4 2025 | — |
| SKYCLARYS fourth quarter U.S. revenue | 89M | Q4 2025 | — |
| SPINRAZA fourth quarter year-over-year revenue change | -15% | Q4 2025 | — |
| VUMERITY fourth quarter year-over-year revenue growth | 3% | Q4 2025 | — |
| ZURZUVAE fourth quarter revenue | 66M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIIB
this stock
Biogen Inc.
|
$31.38B | +21.8% | +2.2% | — | 3.7% |
|
LLY
ELI LILLY & Co
|
$1.21T | +15.8% | +44.7% | 43.0 | 1.0% |
|
JNJ
Johnson & Johnson
|
$658.89B | +29.2% | +6.0% | 31.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$462.68B | +14.6% | +8.6% | 74.0 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$375.50B | +41.5% | +1.3% | 121.8 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIIB | +1.8% | +6.8% | +11.8% | +5.6% | +21.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +3.7% | +3.5% | +0.6% | +3.5% | +10.0% |
Capital returns
Buyback program
· as of Apr 29, 2026
Authorized
$5.00B
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
894 filings
858 filers
Visit website
Investor relations